Русский
Pharmacotherapeutic group:
immunomodulatory agent.
ATC code: [L0Z]
The pharmacological properties
Pharmacodynamics
Azoximer bromide has a complex action: immunomodulatory, detoxicating, antioxidant, anti-inflammatory moderate.
The basis of the mechanism of immunomodulatory action azoximer bromide is a direct effect on the phagocytic cells and natural killer cells, and stimulation of antibody production and synthesis of interferon-alpha and interferon-gamma.
Detoxification and antioxidant svoystvaAzoksimera bromide is largely determined by the structure and nature of the high molecular weight of the drug.
Azoximer bromide increases resistance of the organism against both local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency, caused by different infection, trauma, complications after surgical procedures.
A characteristic feature in the local azoximer bromide (sublingual) use is the ability to activate the early defense against infection factors: drug stimulates bactericidal properties neutrophils, macrophages, enhances their ability to absorb bacteria improves the bactericidal properties of saliva and mucous secretions of the upper respiratory tract.
When administered orally as azoximer bromide activated lymphoid cells into lymph nodes intestine.
Azoximer bromide blocked soluble toxic substances and microparticles has the ability to excrete toxins, heavy metal salts, inhibits lipid peroxidation, both due to the interception of free radicals and by elimination of catalytic ions Fe2 +. Azoximer bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines.
Azoximer bromide well tolerated, has no mitogenic, polyclonal activity, antigenic properties, has no allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.
Azoximer bromide has no smell and taste, has no local irritating effect when applied to the mucous membranes of the nose and oropharynx.
Pharmacokinetics
Azoximer bromide after ingestion is rapidly absorbed from the gastrointestinal tract, bioavailability in oral administration of more than 70%. The maximum plasma concentration is reached after 3 hours after ingestion. FarmakokinetikaAzoksimera bromide is linear (plasma concentration is proportional to the dose).
Azoximer bromide compound is hydrophilic. Apparent volume of distribution is about 0.5 L / kg, suggesting that the drug is distributed mainly in the extracellular fluid. poluabsorbtsii period – 35 minutes, half-life – 18 hours.
Azoksimera bromidbystro distributed to all organs and tissues of the body, penetrates the blood-brain and blood-barrier. The cumulative effect is not. In organizmeAzoksimera bromidpodvergaetsya biodegradation to low molecular weight oligomers derived primarily by the kidneys, with faeces – less than 3%
.
Active substance:
Azoximer bromide
Manufacturer
NGOs Petrovax Farm, Russia
Composition
Active substance:
Azoximer bromide – 12 mg;
Excipients:
mannitol – 3.6 mg,
Povidone K 17 – 2.4 mg,
lactose monohydrate – 185.0 mg,
potato starch – 45.0 mg,
Stearic Acid – 2.0 mg.
Indications
in adults and adolescents over 12 years for the treatment and prevention of infectious and inflammatory diseases (viral, bacterial and fungal etiologies) are not amenable to standard therapy in the acute phase and in remission.
In the treatment of:
- recurrent acute and chronic infectious and inflammatory diseases of the oropharynx, sinus, upper respiratory tract, the inner and middle ear;
- allergic disease complicated by recurrent bacterial, fungal and viral infections (including hay fever, bronchial asthma);
- Rehabilitation frequent and long (more than 4-5 times per year) ill persons.
In monotherapy:
- for the prevention of recurrent herpes infection;
- for prevention of exacerbations of chronic seasonal outbreaks oropharyngeal infections, paranasal sinuses, upper respiratory tract, the inner and middle ear;
- in immunocompromised individuals for the prevention of influenza and other acute respiratory infections in the pre-epidemic period;
- for correction of secondary immunodeficiencies resulting from aging or exposure to adverse factors.
Contraindications
- Increased individual sensitivity;
- pregnancy, breast-feeding;
- Children under 3 years;
- acute renal failure;
- rare hereditary intolerance to lactose, lactase deficiency, glucose-galaktoznoymalabsorbtsii syndrome.
Carefully
If you have a disease, referred to in this section, contact your doctor before taking the drug:
– Chronic renal failure (use no more than 2 times per week).
Side effects
Side effects were recorded.
If you notice any side effects not listed in the instructions, tell your doctor.
How to accept, acceptance rate and dosage
Use according to the drug only indications that the application and in those doses which are specified in the instruction.
If after treatment there is no improvement or symptoms are aggravated, or there are new symptoms, you should consult with your doctor.
Orally and sublingually for 20-30 minutes before meals daily, 2 times a day: children older than 10 years and adults – 1 tablet, children from 3 to 10 years – ½ tablets (6 mg).
If necessary, may conduct repeated courses of therapy in 3-4 months. When the re-appointment of the drug efficacy is not reduced.
The recommended treatment regimen
sublingually
For the treatment of adults:
- influenza and acute respiratory infections – 1 tablet 2 times daily for 7 days;
- inflammation of the oropharynx – 1 tablet 2 times a denv within 10 days;
- exacerbations of chronic respiratory diseases, paranasal sinuses, chronic otitis – 1 tablet 2 times a day for 10 days;
- allergies (including hay fever, bronchial asthma), complicated by recurrent bacterial, fungal and viral infektsiey- 1 tablet 2 times a day for 10 days.
For the treatment of children 3 to 10 years:
- influenza and acute respiratory infections – ½ tablet 2 times daily for 7 days;
- inflammation of the oropharynx – at ½ tablet 2 times a day for 7 days;
- allergic disorders (including hay fever, asthma), complicated by recurrent bacterial, fungal and viral infections – ½ tablet 2 times daily for 7 days
.
For the treatment of children over 10 years:
- influenza and acute respiratory infections – 1 tablet 2 times daily for 7 days;
- inflammation of the oropharynx – 1 tablet 2 times a day for 7 days;
- exacerbations of chronic respiratory diseases, paranasal sinuses, chronic otitis – 1 tablet 2 times a day for 7 days;
- allergic disorders (including hay fever, asthma), complicated by recurrent bacterial, fungal and viral infections – 1 tablet 2 times daily for 7 days
.
For the prevention of adult:
- influenza and acute respiratory infections in the pre-epidemic period – 1 tablet per day for 10 days;
- recurrent herpetic infection and nasal labial – 1 tablet 2 times a day for 10 days;
- exacerbations of chronic foci of infection of the oropharynx, paranasal sinuses, upper respiratory tract, middle and inner ear – 1 tablet once a day for 10 days;
- secondary immunodeficiencies resulting from aging or exposure to adverse factors – 1 tablet 1 time a day for 10 days
.
For the prevention of children from 3 to 10 years:
- influenza and acute respiratory infections in the pre-epidemic period – at ½ tablet per day for 7 days;
- recurrent herpetic infection and nasal labial – at ½ tablet 2 times daily for 7 days;
- exacerbations of chronic foci of infection of the oropharynx, paranasal sinuses, upper respiratory tract, middle and inner ear – at ½ tablet once a day for 10 days
.
For the prevention of children over 10 years:
- influenza and acute respiratory infections in the pre-epidemic period – 1 tablet per day for 7 days;
- recurrent herpetic infection and nasal labial – 1 tablet 2 times daily for 7 days;
- exacerbations of chronic foci of infection of the oropharynx, paranasal sinuses, upper respiratory tract, the middle ear and the inner 1 tablet once a day for 10 days.
orally
For the treatment of adults:
- diseases of the upper and lower respiratory tract infections – 1 tablet with 2 times 10 days
.
For the treatment of children over 10 years:
- diseases of the upper and lower respiratory tract infections – 1 tablet with 2 times 10 days
Storage conditions
At a temperature of 2 to 25 ° C.
Keep out of the reach of children.
Active substance
Azoximer bromide
Interaction
Azoximer bromide does not inhibit isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, cytochrome P-450, and the drug is compatible with antibiotics, antiviral, antifungal and antihistamines, glucocorticosteroids and cytostatics.
If you accept the above or any other medicines (including OTC), before taking polioksidoniya consult your doctor.
Special conditions
With the development of allergic reactions should stop using Polioksidoniy® drug and consult a doctor.
If necessary, discontinuation Polioksidoniy® cancellation can be done immediately without gradual dose reduction.
In the case of missing the next dose administration subsequent its application should be performed in the normal mode, as indicated in the instructions or recommended by a doctor. The patient should not double the dose administered to compensate for missed doses.
Do not use the drug if there is visual evidence of his unfitness (stacking fault discoloration tablets).
Effects on ability to drive vehicles and other mechanisms
Use of the drug Polioksidoniy® does not affect the ability to perform potentially hazardous activities that require high concentration and speed of psychomotor reactions (including means of transport management, work with moving machinery).
Pregnancy and lactation
Polyoxidonium is contraindicated in pregnancy, breast-feeding and children up to 6 months (no clinical experience).
Overdose
Cases of overdose are not logged in.
| Weight | 0.026 kg |
|---|---|
| Expiration date | 2 years. Do not use the medicine after the expiration date printed on the package. |
| Dosage form | tablets |
Related products
Brain enhancing
Joint diseases
Joint diseases
Atherosclerosis
Homeopathy
Medicine
Joint diseases
Immunostimulants
